Gwo Xi Stem Cell Applied Technology Co. , Ltd
Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs. Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of … Read more
Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) - Net Assets
Latest net assets as of June 2025: NT$625.96 Million TWD
Based on the latest financial reports, Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) has net assets worth NT$625.96 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.01 Billion) and total liabilities (NT$387.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$625.96 Million |
| % of Total Assets | 61.78% |
| Annual Growth Rate | 2.2% |
| 5-Year Change | 10.49% |
| 10-Year Change | N/A |
| Growth Volatility | 22.19 |
Gwo Xi Stem Cell Applied Technology Co. , Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Gwo Xi Stem Cell Applied Technology Co. , Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Gwo Xi Stem Cell Applied Technology Co. , Ltd (2019–2024)
The table below shows the annual net assets of Gwo Xi Stem Cell Applied Technology Co. , Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$660.91 Million | -11.20% |
| 2023-12-31 | NT$744.23 Million | +45.84% |
| 2022-12-31 | NT$510.32 Million | +3.69% |
| 2021-12-31 | NT$492.16 Million | -17.72% |
| 2020-12-31 | NT$598.17 Million | +0.93% |
| 2019-12-31 | NT$592.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gwo Xi Stem Cell Applied Technology Co. , Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 9976400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$959.49 Million | 145.18% |
| Total Equity | NT$660.91 Million | 100.00% |
Gwo Xi Stem Cell Applied Technology Co. , Ltd Competitors by Market Cap
The table below lists competitors of Gwo Xi Stem Cell Applied Technology Co. , Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AirBoss of America Corp
OTCQX:ABSSF
|
$57.06 Million |
|
Peak Minerals Ltd
AU:PUA
|
$57.07 Million |
|
Spigen Korea Co. Ltd
KQ:192440
|
$57.07 Million |
|
India Nippon Electricals Limited
NSE:INDNIPPON
|
$57.08 Million |
|
Edda Wind ASA
OL:EWIND
|
$57.04 Million |
|
Frasers Property (Thailand) Public Company Limited
BK:FPT
|
$57.04 Million |
|
CuongThuan Idico Development Investment Corp
VN:CTI
|
$56.99 Million |
|
Emporiki Eisagogiki Aftokiniton Ditrohon kai Mihanon Thalassis Societe Anonyme
AT:MOTO
|
$56.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gwo Xi Stem Cell Applied Technology Co. , Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 744,229,000 to 660,909,000, a change of -83,320,000 (-11.2%).
- Net loss of 83,320,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-83.32 Million | -12.61% |
| Total Change | NT$- | -11.20% |
Book Value vs Market Value Analysis
This analysis compares Gwo Xi Stem Cell Applied Technology Co. , Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.20x to 3.34x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$7.19 | NT$23.00 | x |
| 2020-12-31 | NT$6.73 | NT$23.00 | x |
| 2021-12-31 | NT$5.82 | NT$23.00 | x |
| 2022-12-31 | NT$5.97 | NT$23.00 | x |
| 2023-12-31 | NT$8.31 | NT$23.00 | x |
| 2024-12-31 | NT$6.89 | NT$23.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gwo Xi Stem Cell Applied Technology Co. , Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.61%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.00%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.61x
- Recent ROE (-12.61%) is above the historical average (-16.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -14.04% | -43.54% | 0.17x | 1.93x | NT$-131.73 Million |
| 2020 | -14.26% | -44.66% | 0.16x | 1.99x | NT$-143.26 Million |
| 2021 | -21.88% | -43.48% | 0.22x | 2.25x | NT$-153.79 Million |
| 2022 | -21.97% | -62.05% | 0.17x | 2.05x | NT$-163.14 Million |
| 2023 | -11.84% | -62.40% | 0.12x | 1.65x | NT$-162.51 Million |
| 2024 | -12.61% | -49.00% | 0.16x | 1.61x | NT$-149.41 Million |
Industry Comparison
This section compares Gwo Xi Stem Cell Applied Technology Co. , Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) | NT$625.96 Million | -14.04% | 0.62x | $57.05 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |